How magic mushrooms changed my life
Financial Review, January 19, 2022
So, can psilocybin really help those with depression? I was skeptical, but the retreat changed my mind.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
Psychedelic Stock Watch, January 10, 2022
In 2020, Health Canada began tentative steps to open up legal access to psychedelics-based therapies via “exemptions” granted through its Special Access Program (SAP).
Therapists hail ‘legalization’ of medicinal psychedelic drugs
Calgary Herald, January 7, 2022
Local therapists say Ottawa’s move allowing physicians to prescribe psychedelics is a “seismic shift” towards legalizing their medicinal use.
$14.8 million for innovative mental health clinical trials
Health.gov.au, January 7, 2022
Seven clinical trials testing the use of potential breakthrough combination therapies to treat debilitating mental illnesses will receive a total of almost $15 million from the Australian Government’s Medical Research Future Fund (MRFF).
Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
Benzinga, January 5, 2022
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
Depression and Grief Wrecked a Man’s Life—Until He Took Magic Mushroom Ingredient
Newsweek, December 26, 2021
Five years after taking part in a clinical trial, Kirk Rutter, spoke to Newsweek about his experiences of the trial and its impact on his mental health.
Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms
The Growth Op, December 13, 2021
Three Canadians struggling with mental health conditions have received exemptions to the Controlled Drugs and Substances Act from the federal Minister of Health Jean-Yves Duclos.
Psychedelics for mental illness
ABC News, December 12, 2021
Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at with our Ambassadors Dr Rick Doblin and Professor David Nutt.
‘This isn’t the 60s again’: psychedelics business takes off amid culture clash
The Guardian, December 12, 2021
Experts fear if psychedelics fall exclusively into the hands of big pharma the industry will follow the same path as legal marijuana, making the rich richer.
Psychedelics can change humanity for the better. It’s time to unlock their power
The Guardian, November 26, 2021
Founder and Executive Director at MAPS and an Ambassador for Mind Medicine Australia, Dr Rick Doblin (USA) is at the heart of the psychedelic movement. In this article he shares some of his findings and progress.
Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia
ABC News, November 12, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
Monash presses go on psychedelics to tackle ‘mental health tsunami’
The Sydney Morning Herald, November 10, 2021
Monash University has set its sights on capturing a slice of the multibillion dollar psychedelic medicines market, with the launch of a drug development centre for new psychiatric treatments, including those using MDMA and psilocybin.
New research brings psychedelic drugs a step closer to medical use
ABC - RN Breakfast with Fran Kelly, November 10, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
Major announcement: COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Globe News Wire, November 9, 2021
Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support.
Will the magic of psychedelics transform psychiatry?
The Guardian, November 7, 2021
Imagine a medicine that could help people process disturbing memories, sparking behavioural changes rather than merely burying and suppressing symptoms and trauma.
New research shows how psychedelic medicines can help people with PTSD
Today.com, November 5, 2021
TODAY’s Savannah Guthrie spoke to two patients whose lives have been changed by the therapy.
World-first trial of psilocybin therapy for anxiety disorders to begin in Australia
Happymag, November 1, 2021
Incannex Healthcare, in partnership with Monash University, has obtained ethics approval to begin the first-ever clinical trial investigating the effects of psilocybin assisted psychotherapy to treat generalised anxiety disorder (GAD).
Johns Hopkins Receives $4M From NIH To Study Psilocybin As Tool To Quit Smoking
Ganjapreneur, October 22, 2021
Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.
DEA Wants Way More Cannabis & Psychedelics for Research In 2022
Ganjapreneur, October 18, 2021
The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.
Psychedelic research renaissance: The urgent quest for new mental health medicines
Lens Monash, October 15, 2021
“There’s been a resurgence in research and interest in psychedelic medicine over the past two decades, and particularly so over the past five years,” says Dr Liknaitzky.